The rolling review has reduced the timeline leading up to and including the conditional marketing authorisation. Altogether, these efforts have led to record time in which the vaccines were authorised in the EU as shown in Figure 4: 21 days between Pfizer-BioNTech’s application and the EU’s issuance of the CMA, 36 days for Moderna, 17 days for AstraZeneca and 23 days for Janssen, compared to the standard EU’s review timeline of 210 working days.
Time of COVID-19 vaccines authorisation in the EU
Timeline of COVID-19 vaccines authorisations in the EU
Categories:
European Parliamentary Research Service
Related Articles
We write about
Disclaimer and Copyright statement
The content of all documents (and articles) contained in this blog is the sole responsibility of the author and any opinions expressed therein do not necessarily represent the official position of the European Parliament. It is addressed to the Members and staff of the EP for their parliamentary work. Reproduction and translation for non-commercial purposes are authorised, provided the source is acknowledged and the European Parliament is given prior notice and sent a copy.
For a comprehensive description of our cookie and data protection policies, please visit Terms and Conditions page.
Copyright © European Union, 2014-2025. All rights reserved.




Be the first to write a comment.